Vaxart, Inc. (NASDAQ:VXRT) Director Wouter Latour sold 333,334 shares of the stock in a transaction on Monday, November 23rd. The shares were sold at an average price of $6.32, for a total value of $2,106,670.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of VXRT stock traded up $0.71 on Monday, reaching $7.12. 12,359,178 shares of the company were exchanged, compared to its average volume of 16,960,246. The company has a market cap of $778.87 million, a price-to-earnings ratio of -12.06 and a beta of -0.11. The company has a 50-day moving average of $5.79 and a 200-day moving average of $6.40. Vaxart, Inc. has a one year low of $0.28 and a one year high of $17.49.
Vaxart (NASDAQ:VXRT) last released its quarterly earnings data on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.01. Vaxart had a negative net margin of 281.50% and a negative return on equity of 84.90%. Equities research analysts predict that Vaxart, Inc. will post -0.35 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd bought a new position in shares of Vaxart during the 3rd quarter worth about $34,000. Ameritas Investment Partners Inc. bought a new position in shares of Vaxart during the 2nd quarter worth about $35,000. PNC Financial Services Group Inc. boosted its position in shares of Vaxart by 39.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,451 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 1,270 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Vaxart during the 2nd quarter worth about $63,000. Finally, Raymond James & Associates bought a new position in shares of Vaxart during the 3rd quarter worth about $70,000. 17.90% of the stock is currently owned by institutional investors.
A number of analysts recently weighed in on the company. BidaskClub downgraded Vaxart from a "sell" rating to a "strong sell" rating in a report on Friday, October 23rd. HC Wainwright increased their price objective on Vaxart from $7.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Zacks Investment Research downgraded Vaxart from a "hold" rating to a "sell" rating in a report on Saturday, November 14th. Finally, B. Riley decreased their price target on Vaxart from $22.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday, November 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The company presently has an average rating of "Hold" and a consensus price target of $11.42.
About Vaxart
Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
Recommended Story: How Investors Use a Balance Sheet
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Top Ten Brokerages You Can Trust
There are more than 500 brokerages and research houses that hire analysts to issue ratings and recommendations. Collectively, these brokerages and their analysts publish approximately 250,000 ratings each year. Every trading day, there are nearly 700 reports and recommendations that are released to the public. To say that it's difficult to separate the signal from the noise when interpreting this data would be an understatement.
MarketBeat has developed a system to track each brokerage and research house's stock recommendations and score them based on their past performance. If Goldman Sachs predicted that Apple's stock price would hit $150.00 on a specific date, how accurate were they? If Bank of America issued a "strong-buy" rating on a stock, how did that stock perform compared to the broader market over the following twelve months? This tracking system has been applied to the 1,000,000+ ratings that MarketBeat has tracked during the last ten years to identify which brokerages you can really trust (and which you can safely ignore).
This slide show lists the 10 brokerages who have issued the most accurate analyst recommendations over the past several years, as measured by the performance of their "buy" ratings and the accuracy of their price targets.
View the "Top Ten Brokerages You Can Trust".
